Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells

DNA and Cell Biology

Volumn 33, Issue 5, 2014, Pages 275-281

  Xu, Ming ^a   Zheng, Yan Ling ^a   Xie, Xiao Yan ^a   Liang, Jin Yu ^a   Pan, Fu Shun ^a   Zheng, Shu Guang ^a   Lü, Ming De ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; SORAFENIB; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COBALT; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899706846     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2013.2184     Document Type: Article

References (21)

1. Brown, J.M., and Giaccia, A.J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
2. Bruix, J., and Llovet, J.M. (2002). Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35, 519-524.
3. Cho, Y.K., Rhim, H., and Noh, S. (2011). Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol 26, 1354-1360.
4. Falk, W., Goodwin, R.J., and Leonard, E.J. (1980). A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods 33, 239-247.
5. Ferrara, N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25, 581-611.
6. Hoffmann, K., Glimm, H., Radeleff, B., Richter, G., Heining, C., Schenkel, I., Zahlten-Hinguranage, A., Schirrmacher, P., Schmidt, J., Buchler, M.W., Jaeger, D., von Kalle, C., and Schemmer, P. (2008). Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8, 349.
7. Koda, M., Maeda, Y., Matsunaga, Y., Mimura, K., Murawaki, Y., and Horie, Y. (2003). Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 27, 163-167.
8. Kuvshinoff, B.W., and Ota, D.M. (2002). Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 132, 605-611; discussion 611-612.
9. Lau, W.Y., and Lai, E.C. (2009). The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 249, 20-25.
10. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., and Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
11. Mulier, S., Ni, Y., Jamart, J., Ruers, T., Marchal, G., and Michel, L. (2005). Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242, 158-171.
12. Pawlik, T.M., Izzo, F., Cohen, D.S., Morris, J.S., and Curley, S.A. (2003). Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 10, 1059-1069.
13. Peng, X.H., Karna, P., Cao, Z., Jiang, B.H., Zhou, M., and Yang, L. (2006). Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 281, 25903-25914.
14. Portolani, N., Tiberio, G.A., Ronconi, M., Coniglio, A., Ghidoni, S., Gaverini, G., and Giulini, S.M. (2003). Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 50, 2179-2184.
15. Seki, T., Tamai, T., Ikeda, K., Imamura, M., Nishimura, A., Yamashiki, N., Nakagawa, T., and Inoue, K. (2001). Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 13, 291-294.
16. Semenza, G.L. (2002). HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8, S62-S67.
17. Semenza, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732.
18. Svendsen, M.N., Werther, K., Nielsen, H.J., and Kristjansen, P.E. (2002). VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 37, 373-379.
19. Takada, Y., Kurata, M., and Ohkohchi, N. (2003). Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 8, 332-335.
20. van der Bilt, J.D., Kranenburg, O., Nijkamp, M.W., Smakman, N., Veenendaal, L.M., Te, V.E., Voest, E.E., van Diest, P.J., and Borel, R.I. (2005). Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 42, 165-175.
21. Wang, G.L., Jiang, B.H., Rue, E.A., and Semenza, G.L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92, 5510-5514.